Company Overview

Fortrea Holdings Inc. is a global contract research organization (CRO) that provides clinical development solutions to the biopharmaceutical, biotechnology, and medical device industries. The company focuses on supporting drug and therapy development across the full clinical trial lifecycle, primarily serving mid-sized and large pharmaceutical companies as well as emerging biotechnology firms. Its services are designed to help clients accelerate development timelines, manage regulatory complexity, and generate clinical evidence required for product approval.

Fortrea was established in 2023 following the spin-off of Labcorp’s Clinical Development business, creating a standalone, publicly traded CRO with a singular focus on clinical research services. The company positions itself as a scientifically driven partner with deep therapeutic expertise, global scale, and an emphasis on operational rigor. Its strategic differentiation centers on therapeutic depth, especially in complex and late-stage clinical trials, and long-standing relationships with global biopharma sponsors.

Business Operations

Fortrea generates revenue primarily through fee-for-service clinical development contracts, offering capabilities across Clinical Pharmacology, Phase I–IV Clinical Development, Decentralized Clinical Trials, and Post-Approval and Real-World Evidence Services. These offerings span study design, site management, patient recruitment, data management, biostatistics, regulatory consulting, and safety monitoring. Revenue is typically recognized over the duration of clinical trials, which can extend multiple years.

Operations are conducted through a globally integrated delivery model, with centralized scientific leadership and regionally distributed operational teams. Fortrea controls clinical trial infrastructure, proprietary operational platforms, and therapeutic expertise developed over decades within Labcorp. The company operates through wholly owned subsidiaries rather than joint ventures, and no material equity-method joint ventures have been consistently disclosed in public filings.

Strategic Position & Investments

Fortrea’s strategy emphasizes organic growth through increased share of wallet with existing clients, expansion in high-growth therapeutic areas, and improved operational efficiency following its separation from Labcorp. Key growth initiatives include strengthening capabilities in oncology, cell and gene therapy, rare diseases, and decentralized and hybrid trial models, which are increasingly востребованы by sponsors seeking faster and more patient-centric trial execution.

Since becoming an independent company, Fortrea has prioritized balance sheet stabilization, standalone system implementation, and selective internal investment rather than large-scale acquisitions. Public disclosures indicate limited material acquisitions post-spin, with capital allocation focused on technology enablement, workforce specialization, and global delivery optimization. Data inconclusive based on available public sources regarding any significant post-spin acquisitions.

Geographic Footprint

Fortrea maintains a global operational presence spanning North America, Europe, Asia-Pacific, and Latin America, with its corporate headquarters located in Durham, North Carolina, United States. The company supports clinical trials in more than 100 countries, leveraging regional offices, clinical sites, and operational hubs to meet local regulatory and patient recruitment requirements.

Its international footprint enables Fortrea to conduct large, multinational clinical programs and support region-specific regulatory submissions. The company’s scale in Europe and Asia-Pacific is particularly important for late-stage global trials, while North America remains its largest revenue-generating region. Operations are structured to allow cross-border trial coordination and centralized data oversight.

Leadership & Governance

Fortrea is led by an executive team with extensive experience in clinical research, biopharmaceutical development, and global operations. Leadership emphasizes scientific rigor, client partnership, and disciplined execution as core elements of the company’s strategic vision as an independent CRO.

Key executives include:

• Thomas Pike – Chief Executive Officer
• Jason Altman – Chief Financial Officer
• Sue McGuire – Chief Operations Officer
• Michael Bell – Chief Strategy Officer
• Stephanie Brogdon – Chief Human Resources Officer

The company is governed by a board of directors composed primarily of independent members with backgrounds in life sciences, healthcare services, and public company governance, consistent with U.S. public company standards.